• Distinct Apoptotic Pathways in BMECs Induced by Candida krus

  2026-05-18

  This study reveals that the yeast and hypha forms of Candida krusei induce apoptosis in bovine mammary epithelial cells (BMECs) through distinct molecular pathways, highlighting novel mechanistic insights into mycotic mastitis pathogenesis. These findings provide a refined framework for targeted apoptosis inhibition and potential translational strategies in veterinary research.

• 10058-F4: c-Myc-Max Dimerization Inhibitor for Apoptosis Res

  2026-05-18

  10058-F4 is a small-molecule inhibitor that selectively disrupts c-Myc-Max dimerization, suppressing oncogenic transcription and promoting apoptosis in cancer models. Its robust activity in acute myeloid leukemia and prostate cancer xenografts, alongside well-characterized solubility and handling parameters, makes it a key reagent for apoptosis assays and c-Myc pathway interrogation.

• FLAG tag Peptide (DYKDDDDK): Advanced Utility in Exosome Bio

  2026-05-17

  Explore the unique applications of the FLAG tag Peptide (DYKDDDDK) in exosome and vesicular protein research. This in-depth analysis reveals advanced assay design strategies and integrates new mechanistic insights for recombinant protein detection.

• TSPAN18-STIM1 Axis Drives Bone Metastasis in Prostate Cancer

  2026-05-16

  Zhou et al. uncover a novel mechanism by which TSPAN18 promotes bone metastasis in prostate cancer through stabilization of STIM1 and enhancement of calcium signaling. This work provides mechanistic insight into metastatic progression and highlights potential new targets for therapeutic intervention in hormone-responsive cancer research.

• Heparin Sodium: Advanced Protocols for Thrombosis Research

  2026-05-15

  Heparin sodium, a benchmark glycosaminoglycan anticoagulant from APExBIO, empowers translational thrombosis research with high reproducibility and versatile delivery strategies. This guide details experimental protocols, troubleshooting, and innovative applications—bridging recent plant nanovesicle findings to optimize anti-factor Xa and aPTT assays.

• ALDOB K87 Lactylation Regulates Mitochondrial Dynamics in PH

  2026-05-15

  This study identifies ALDOB K87 lactylation as a pivotal driver of mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH). The findings illuminate the lactate–ALDOB–DRP1 signaling axis, revealing new mechanistic insights with potential translational value for vascular remodeling research.

• Tofacitinib Reverses Inflammation & Mitochondrial Dysfunctio

  2026-05-14

  This study demonstrates that tofacitinib (CP-690550) uniquely reverses both inflammatory and mitochondrial defects in GM-CSF-reprogrammed macrophages from rheumatoid arthritis (RA) patients. By targeting STAT5 signaling and metabolic pathways, tofacitinib offers mechanistic advantages over conventional cytokine or metabolic interventions, with implications for improving RA research models and therapeutic development.

• AEBSF.HCl in Lysosomal Protease Control: A New Cellular Fron

  2026-05-14

  Explore the multifaceted role of AEBSF.HCl (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) in regulating lysosomal protease activity, necroptosis, and neurodegenerative pathways. This article delivers unique practical insights for advanced cell death and amyloid research using this broad-spectrum inhibitor.

• Dabigatran Etexilate: Direct Thrombin Inhibitor in Research

  2026-05-13

  Dabigatran etexilate stands out as a direct thrombin inhibitor, enabling reproducible anticoagulant research and precise modulation of the coagulation cascade. Explore practical workflows, comparative advantages, and troubleshooting strategies for maximizing data quality in atrial fibrillation and stroke prevention models.

• BI 2536 in Precision Cell Cycle Disassembly: Mechanistic Ins

  2026-05-13

  Explore how BI 2536, a potent PLK1 inhibitor, uniquely enables precise dissection of mitotic checkpoint complex disassembly in cancer research. Gain mechanistic clarity and advanced protocol guidance rooted in breakthrough reference discoveries.

• Dabigatran Etexilate: Innovations in Direct Thrombin Inhibit

  2026-05-12

  This article reviews the pivotal clinical evaluation of dabigatran etexilate as a novel oral direct thrombin inhibitor. It highlights the drug’s mechanistic advantages, predictable pharmacokinetics, and clinical efficacy in anticoagulation, emphasizing its impact on stroke prevention in atrial fibrillation and venous thromboembolism prophylaxis.

• L1023 Anti-Cancer Compound Library: Workflow, Applications &

  2026-05-12

  Accelerate cancer drug discovery with the L1023 Anti-Cancer Compound Library, a rigorously curated resource powering high-throughput screening and precision pathway interrogation. This article unpacks practical workflows, troubleshooting tips, and advanced applications, translating recent breakthroughs into actionable assay strategies.

• Dabigatran (Pradaxa): Applied Thrombin Inhibition in Researc

  2026-05-11

  Dabigatran (Pradaxa) sets a new benchmark for in vitro thrombin inhibition, offering unmatched specificity for coagulation function tests and translational models of stroke and thrombosis. This deep-dive explores practical workflows, troubleshooting, and advanced applications—empowering anticoagulation researchers with rigor and flexibility.

• Antidepressant Actions of Rotigotine: Evidence from Preclini

  2026-05-11

  This article examines the antidepressant effects of rotigotine, a dopamine D2/D3 receptor agonist, in validated rodent models of depression. The findings highlight rotigotine's capacity to reverse depressive-like behaviors at specific dosing regimens, with implications for research on Parkinson's disease comorbidities and dopaminergic signaling.

• CARM1-Targeted Peptide Suppresses Breast Cancer Progression

  2026-05-10

  This study introduces a highly selective peptide inhibitor of CARM1 (Pi-CARM1-TAT) that curbs breast cancer cell proliferation and tumor growth, both in vitro and in vivo. The peptide demonstrates potential to overcome endocrine therapy resistance, offering a novel avenue for therapeutic development in hormone receptor-positive breast cancer.

16787 records 1/1120 page Next 12345 下5页 Last page